Novo Nordisk, the maker of Ozempic and Wegovy weight-loss drugs, just regained the title as Europe’s most valuable company ...

NVO advances obesity pipeline with CagriSema and Amycretin while expanding through major deals amid rising competition.

Wegovy maker Novo Nordisk has hired the start-up Deep Apple Therapeutics to develop small molecules as its next weight-loss ...

Danish drugmaker Novo Nordisk is teaming up with California-based biotech Septerna to develop new pills to treat obesity, type 2 diabetes and other metabolic diseases. The deal could be worth up ...

Novo Nordisk NVO shares have gained 5.8% in a week. The uptrend in the stock price was driven by reports of an activist hedge ...

Novo Nordisk and Septerna plan to create new obesity pills that target G protein-coupled receptors (GPCRs), including GLP-1, GIP, and glucagon. HealthDay News — Danish drugmaker Novo Nordisk is ...

Novo Nordisk and Septerna will jointly carry out research on the candidates from discovery to development candidate selection, with the Danish pharma group taking over responsibility as they ...

HealthDay News — Danish drugmaker Novo Nordisk is teaming up with California-based biotech Septerna to develop new pills to treat obesity, type 2 diabetes and other metabolic diseases.

Novo Nordisk reached an important R&D milestone on May 14, announcing a deal worth up to $2.2 billion with Septerna to develop drugs to treat obesity and other cardiometabolic diseases.

Novo Nordisk Places Bet on CEO Shake-Up to Regain ... for early-stage candidates like Amycretin and others bought from Septerna and United Laboratories International show the company's transition ...

A key catalyst was Novo Nordisk’s recent $2.2 billion exclusive global collaboration and licensing deal with Septerna for developing and commercializing oral small-molecule medicines for ...